Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

394.28 +0.80 (+0.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,323,803
Open 394.72
Bid (Size) 391.08 (3)
Ask (Size) 394.29 (2)
Prev. Close 393.48
Today's Range 391.25 - 396.98
52wk Range 316.43 - 448.40
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Vertex Pharmaceuticals Stock a Millionaire Maker?
Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more? 
Via The Motley Fool
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga

Performance

YTD
-4.05%
-4.05%
1 Month
-5.04%
-5.04%
3 Month
-8.94%
-8.94%
6 Month
+8.08%
+8.08%
1 Year
+20.04%
+20.04%

More News

Read More
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
Via The Motley Fool
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today
Via Benzinga
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals
Via Benzinga
Vertex Pharmaceuticals: Buy, Sell, or Hold?
Via The Motley Fool
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
Via The Motley Fool
Could This Stock Be the Next Biotech Buyout?
Via The Motley Fool
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Via Benzinga
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock
Via InvestorPlace
Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Via Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
Via Investor's Business Daily
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
Vertex to Announce First Quarter 2024 Financial Results on May 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
Via The Motley Fool
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
Via Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.